Ionis Pharmaceuticals Inc (IONS) Institutional Ownership & 13F Filings (Q2 2026)

IONS ranks #1125 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

IONS is a top-conviction position for Tweedy, Browne Co LLC — at 13.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IONS belongs to FMR LLC, but the position matters far more to Tweedy, Browne Co LLC, who has 13.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Royal Bank Of Canada has added to its IONS position for two straight quarters, increasing it by $396.0M to reach $490.2M today.

T. Rowe Price has trimmed its IONS position for two straight quarters, cutting it by $406.6M while still holding $313.9M.

IONS is down 0.3% today, but institutions show net buying of $2.1B this quarter — a divergence between today's price move and the underlying institutional flow.

IONS reported a net loss of $565.2M over the trailing twelve months.

• Not yet profitable — net loss of $565.2M over the trailing twelve months
• Revenue declined 7.4% year over year
• Net income declined year over year, from -$268.2M to -$565.2M
• Operating cash flow was negative, using $268.6M in cash
• Current ratio of 3.83x — enough short-term assets to cover short-term liabilities
• Liabilities run 6.20x equity — a highly leveraged balance sheet worth noting